Entheon announces a new partnership to advance its psychedelic drug R&D.
Entheon announces a new partnership to advance its psychedelic drug R&D.
Cybin's bought deal financing has been upsized to CAD$30 million.
The U.S. election has become a major political circus. With investors distracted and the media focused elsewhere, psychedelic stocks are temporarily at low tide.
Cybin Corp announces a CAD$20 million financing at a unit price of CAD$2.25.
Entheon acquires a genetic screening company to identify genetic markers that affect reactions to hallucinogenic drugs.
Mydecine's bought-deal financing is upsized by 50% to CAD $15 million.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now